CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $49.59, indicating a -0.56% change from the previous session's end. The stock's change was less than the S&P 500's daily loss of 0.29%.

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

Crispr Therapeutics 40% share in Casgevy could result in revenue annual between $1.2 billion and $2.8 billion towards the end ...

CRISPR Therapeutics AG (CRSP) closed the latest trading day at $45.51, indicating a +1.42% change from the previous session's end. The stock outpaced the S&P 500's daily gain of 0.45%. Elsewhere ...

Given all these factors, it seems reasonable to assume that Casgevy could grab at least a decent share, perhaps 20% of its ...

Gene therapy-related stocks are poised to end the session in the green, riding high after Sarepta 's (SRPT +7.1%) bullish news yesterday.Seleted tickers: (SLDB -18.6%)(FCSC... The USPTO has ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

The fund earns an Above Average Process Pillar rating. The fund fully replicates its CRSP US Small Cap Index benchmark, which sweeps in the bottom 85%-98% of the US equity market by market capi.